These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
368 related articles for article (PubMed ID: 345572)
1. The hepatic toxicity of antituberculosis regimens containing isoniazid, rifampicin and pyrazinamide. Girling DJ Tubercle; 1978 Mar; 59(1):13-32. PubMed ID: 345572 [TBL] [Abstract][Full Text] [Related]
2. [Effectiveness and problems of PZA-containing 6-month regimen for the treatment of new pulmonary tuberculosis patients]. Wada M Kekkaku; 2001 Jan; 76(1):33-43. PubMed ID: 11211781 [TBL] [Abstract][Full Text] [Related]
3. Hepatic toxicity in South Indian patients during treatment of tuberculosis with short-course regimens containing isoniazid, rifampicin and pyrazinamide. Parthasarathy R; Sarma GR; Janardhanam B; Ramachandran P; Santha T; Sivasubramanian S; Somasundaram PR; Tripathy SP Tubercle; 1986 Jun; 67(2):99-108. PubMed ID: 3775870 [TBL] [Abstract][Full Text] [Related]
4. Side-effects of drug regimens used in short-course chemotherapy for pulmonary tuberculosis. A controlled clinical study. Zierski M; Bek E Tubercle; 1980 Mar; 61(1):41-9. PubMed ID: 6989067 [TBL] [Abstract][Full Text] [Related]
5. Adverse reactions to short-course regimens containing streptomycin, isoniazid, pyrazinamide and rifampicin in Hong Kong. Tubercle; 1976 Jun; 57(2):81-95. PubMed ID: 134476 [TBL] [Abstract][Full Text] [Related]
6. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial. Jasmer RM; Saukkonen JJ; Blumberg HM; Daley CL; Bernardo J; Vittinghoff E; King MD; Kawamura LM; Hopewell PC; Ann Intern Med; 2002 Oct; 137(8):640-7. PubMed ID: 12379063 [TBL] [Abstract][Full Text] [Related]
7. Hepatotoxicity of pyrazinamide: cohort and case-control analyses. Chang KC; Leung CC; Yew WW; Lau TY; Tam CM Am J Respir Crit Care Med; 2008 Jun; 177(12):1391-6. PubMed ID: 18388355 [TBL] [Abstract][Full Text] [Related]
8. [The effectiveness of pyrazinamide-containing six-month short course chemotherapy]. Wada M Kekkaku; 2000 Nov; 75(11):665-73. PubMed ID: 11140090 [TBL] [Abstract][Full Text] [Related]
9. A controlled trial of a 4-weekly supplement of rifampicin, pyrazinamide and streptomycin in the continuation phase of a 7-month daily chemotherapy regimen for pulmonary tuberculosis. Tanzania/British Medical Research Council Collaborative Investigation. S Afr Med J; 1996 Aug; 86(8):960-5. PubMed ID: 8823423 [TBL] [Abstract][Full Text] [Related]
10. Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide. Results at 30 months. Hong Kong Chest Service/British Medical Research Council. Am Rev Respir Dis; 1991 Apr; 143(4 Pt 1):700-6. PubMed ID: 1901199 [TBL] [Abstract][Full Text] [Related]
11. Inactive hepatitis B surface antigen carrier state and hepatotoxicity during antituberculosis chemotherapy. Lee BH; Koh WJ; Choi MS; Suh GY; Chung MP; Kim H; Kwon OJ Chest; 2005 Apr; 127(4):1304-11. PubMed ID: 15821209 [TBL] [Abstract][Full Text] [Related]
12. Effects of two pulmonary tuberculosis drug treatments and acetylator status on liver function in a Zimbabwean population. Neill P; Pringle D; Mhonda M; Kusema T; Nhachi CF Cent Afr J Med; 1990 Apr; 36(4):104-7. PubMed ID: 2225025 [TBL] [Abstract][Full Text] [Related]
13. Assessment of a combined preparation of isoniazid, rifampicin and pyrazinamide (Rifater) in the initial phase of chemotherapy in three 6-month regimens for smear-positive pulmonary tuberculosis: a five-year follow-up report. Teo SK Int J Tuberc Lung Dis; 1999 Feb; 3(2):126-32. PubMed ID: 10091877 [TBL] [Abstract][Full Text] [Related]
14. [Assessment of the use of a multicomponent drug in the treatment of new cases of pulmonary tuberculosis]. Semenova OV Probl Tuberk Bolezn Legk; 2003; (11):22-5. PubMed ID: 14689793 [TBL] [Abstract][Full Text] [Related]
15. [Pyrazinamide versus ethambutol in short-term therapy of lung tuberculosis. A randomized study]. Fiala W; Häcki MA; Brändli O Schweiz Med Wochenschr; 1983 Dec; 113(51):1956-9. PubMed ID: 6658432 [TBL] [Abstract][Full Text] [Related]
16. Randomised trial of thiacetazone and rifampicin-containing regimens for pulmonary tuberculosis in HIV-infected Ugandans. The Makerere University-Case Western University Research Collaboration. Okwera A; Whalen C; Byekwaso F; Vjecha M; Johnson J; Huebner R; Mugerwa R; Ellner J Lancet; 1994 Nov; 344(8933):1323-8. PubMed ID: 7526098 [TBL] [Abstract][Full Text] [Related]
17. A controlled trial of six months chemotherapy in pulmonary tuberculosis. First Report: results during chemotherapy. British Thoracic Association. Br J Dis Chest; 1981 Apr; 75(2):141-53. PubMed ID: 7023526 [TBL] [Abstract][Full Text] [Related]
18. [Short-term therapy of lung tuberculosis using a fixed combination of isoniazid, rifampicin and pyrazinamide. Results after 2 years]. Brändli O; Haegi V; Villiger B; Bohn W; Baumann HR; Zäch R Schweiz Med Wochenschr; 1989 Mar; 119(10):299-305. PubMed ID: 2652281 [TBL] [Abstract][Full Text] [Related]
19. Predisposing factors in hepatitis induced by isoniazid-rifampin treatment of tuberculosis. Grönhagen-Riska C; Hellstrom PE; Fröseth B Am Rev Respir Dis; 1978 Sep; 118(3):461-6. PubMed ID: 707874 [TBL] [Abstract][Full Text] [Related]
20. Assessment of a daily combined preparation of isoniazid, rifampin, and pyrazinamide in a controlled trial of three 6-month regimens for smear-positive pulmonary tuberculosis. Singapore Tuberculosis Service/British Medical Research Council. Am Rev Respir Dis; 1991 Apr; 143(4 Pt 1):707-12. PubMed ID: 1901200 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]